All In Biotech

Drug Trial Radar · NCT06465108

Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate the Safety, Pharmacokinetics, and Efficacy of MBX 2109 in Patients With Hypoparathyroidism (Avail Study)

Last checked: Nov 20, 2026Latest source record: Mar 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

64

Actual

Start

Aug 8, 2024

Primary completion

May 23, 2025

Study completion Jun 4, 2025

Sponsor

Lead sponsor
MBX BiosciencesIndustry
Sponsor type
Industry
First posted
Jun 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the safety and tolerability of MBX 2109 administered once weekly to patients with hypoparathyroidism.

Conditions

  • Hypoparathyroidism

Interventions

  • MBX 2109Drug

    Supplied as 1.5 mg per vial reconstituted in 1.4 mL water for injection to a concentration of 1.0 mg/mL

  • PlaceboOther

    Supplied in 1.4 mL water for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the effect of pooled weekly doses of MBX 2109 on the proportion of responder patients defined by serum calcium levels and treatment with active vitamin D and calcium supplements at Week 12/Visit 15Time frame: Week 12

Locations

33 sites in 3 countries. Site status is shown where the registry gives one.

  • MBX Biosciences Investigational Site

    Sacramento, California

  • MBX Biosciences Investigational Site

    Jacksonville, Florida

  • MBX Biosciences Investigational Site

    Jacksonville, Florida

  • MBX Biosciences Investigational Site

    Miami, Florida

  • MBX Biosciences Investigational Site

    Macon, Georgia

  • MBX Biosciences Investigational Site

    Chicago, Illinois

  • MBX Biosciences Investigational Site

    Chicago, Illinois

  • MBX Biosciences Investigational Site

    Jackson, Mississippi

  • MBX Biosciences Investigational Site

    St Louis, Missouri

  • MBX Biosciences Investigational Site

    Omaha, Nebraska

  • MBX Biosciences Investigational Site

    Las Vegas, Nevada

  • MBX Biosciences Investigational Site

    Reno, Nevada

  • MBX Biosciences Investigational Site

    Albany, New York

  • MBX Biosciences Investigational Site

    Great Neck, New York

  • MBX Biosciences Investigational Site

    New York, New York

  • MBX Biosciences Investigational Site

    The Bronx, New York

  • MBX Biosciences Investigational Site

    Greenville, North Carolina

  • MBX Biosciences Investigational Site

    Cleveland, Ohio

  • MBX Biosciences Investigational Site

    Columbus, Ohio

  • MBX Biosciences Investigational Site

    Philadelphia, Pennsylvania

  • MBX Biosciences Investigational Site

    Dallas, Texas

  • MBX Biosciences Investigational Site

    El Paso, Texas

  • MBX Biosciences Investigational Site

    Fort Worth, Texas

  • MBX Biosciences Investigational Site

    Round Rock, Texas

  • MBX Biosciences Investigational Site

    San Antonio, Texas

  • MBX Biosciences Investigational Site

    Weslaco, Texas

  • MBX Biosciences Investigational Site

    Madison, Wisconsin

  • MBX Biosciences Investigational Site

    Córdoba, Argentina

  • MBX Biosciences Investigational Site

    San Miguel de Tucumán, Argentina

  • MBX Biosciences Investigational Site

    CABA, Buenos Aires, Argentina

  • MBX Biosciences Investigational Site

    CABA, Buenos Aires, Argentina

  • MBX Biosciences Investigational Site

    Río Cuarto, Córdoba Province, Argentina

  • MBX Biosciences Investigational Site

    Samsun, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.